Search Results - "Gurney, Mark E"

Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis by Zhou, Mengshi, Xu, Rong, Kaelber, David C, Gurney, Mark E

“…This large, retrospective case-control study of electronic health records from 56 million unique adult patients examined whether or not treatment with a Tumor…”
Get full text

The Use of Facebook Advertising to Recruit Healthy Elderly People for a Clinical Trial: Baseline Metrics by Cowie, Julie M, Gurney, Mark E

“…This report provides data on the use of social media advertising as a clinical trial recruitment strategy targeting healthy volunteers aged 60 years and older…”
Get full text

Genetic Association of Phosphodiesterases With Human Cognitive Performance by Gurney, Mark E

“…Recent, large-scale, genome-wide association studies (GWAS) provide a first view of the genetic fine structure of cognitive performance in healthy individuals…”
Get full text

Effects of chronic inhibition of phosphodiesterase-4D on behavior and regional rates of cerebral protein synthesis in a mouse model of fragile X syndrome by Rosenheck, Michael, Sheeler, Carrie, Saré, Rachel Michelle, Gurney, Mark E., Smith, Carolyn Beebe

“…Fragile X Syndrome (FXS) is caused by silencing the FMR1 gene which results in intellectual disability, hyperactivity, sensory hypersensitivity, autistic-like…”
Get full text

Structural basis for the design of selective phosphodiesterase 4B inhibitors by Fox, David, Burgin, Alex B., Gurney, Mark E.

“…Phosphodiesterase-4B (PDE4B) regulates the pro-inflammatory Toll Receptor –Tumor Necrosis Factor α (TNFα) pathway in monocytes, macrophages and microglial…”
Get full text

Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury by Wilson, Nicole M, Gurney, Mark E, Dietrich, W Dalton, Atkins, Coleen M

“…Traumatic brain injury (TBI) initiates a deleterious inflammatory response that exacerbates pathology and worsens outcome. This inflammatory response is…”
Get full text

Gut-microbiota-microglia-brain interactions in Alzheimer's disease: knowledge-based, multi-dimensional characterization by Wang, QuanQiu, Davis, Pamela B, Qi, Xin, Chen, Shu G, Gurney, Mark E, Perry, George, Doraiswamy, P Murali, Xu, Rong

“…Interactions between the gut microbiota, microglia, and aging may modulate Alzheimer's disease (AD) pathogenesis but the precise nature of such interactions is…”
Get full text

Auditory N1 event-related potential amplitude is predictive of serum concentration of BPN14770 in fragile X syndrome by Norris, Jordan E, Berry-Kravis, Elizabeth M, Harnett, Mark D, Reines, Scott A, Reese, Melody A, Outterson, Abigail H, Michalak, Claire, Furman, Jeremiah, Gurney, Mark E, Ethridge, Lauren E

“…Abstract Fragile X syndrome (FXS) is a rare neurodevelopmental disorder caused by a CGG repeat expansion ≥ 200 repeats in 5’ untranslated region of the FMR1…”
Get full text

The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke by Stefansson, Kari, Helgadottir, Anna, Manolescu, Andrei, Thorleifsson, Gudmar, Gretarsdottir, Solveig, Jonsdottir, Helga, Thorsteinsdottir, Unnur, Samani, Nilesh J, Gudmundsson, Gudmundur, Grant, Struan F A, Thorgeirsson, Gudmundur, Sveinbjornsdottir, Sigurlaug, Valdimarsson, Einar M, Matthiasson, Stefan E, Johannsson, Halldor, Gudmundsdottir, Olof, Gurney, Mark E, Sainz, Jesus, Thorhallsdottir, Margret, Andresdottir, Margret, Frigge, Michael L, Topol, Eric J, Kong, Augustine, Gudnason, Vilmundur, Hakonarson, Hakon, Gulcher, Jeffrey R

“…We mapped a gene predisposing to myocardial infarction to a locus on chromosome 13q12-13. A four-marker single-nucleotide polymorphism (SNP) haplotype in this…”
Get full text

A Novel PDE4D Inhibitor BPN14770 Reverses Scopolamine-Induced Cognitive Deficits via cAMP/SIRT1/Akt/Bcl-2 Pathway by Wang, Yulu, Gao, Shichao, Zheng, Victor, Chen, Ling, Ma, Min, Shen, Shichen, Qu, Jun, Zhang, Hanting, Gurney, Mark E, O'Donnell, James M, Xu, Ying

“…A global, quantitative proteomics/systems-biology analysis of the selective pharmacological inhibition of phosphodiesterase-4D (PDE4D) revealed the…”
Get full text

Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy by Butchbach, Matthew E.R., Singh, Jasbir, Þorsteinsdóttir, Margrét, Saieva, Luciano, Slominski, Elzbieta, Thurmond, John, Andrésson, Thorkell, Zhang, Jun, Edwards, Jonathan D., Simard, Louise R., Pellizzoni, Livio, Jarecki, Jill, Burghes, Arthur H.M., Gurney, Mark E.

“…Proximal spinal muscular atrophy (SMA), one of the most common genetic causes of infant death, results from the selective loss of motor neurons in the spinal…”
Get full text

COVID‐19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US by Wang, QuanQiu, Davis, Pamela B., Gurney, Mark E., Xu, Rong

“…Introduction At present, there is limited data on the risks, disparity, and outcomes for COVID‐19 in patients with dementia in the United States. Methods This…”
Get full text

Formation of High Molecular Weight Complexes of Mutant Cu,Zn-Superoxide Dismutase in a Mouse Model for Familial Amyotrophic Lateral Sclerosis by Johnston, Jennifer A., Dalton, Muffie J., Gurney, Mark E., Kopito, Ron R.

“…Deposition of aggregated protein into neurofilament-rich cytoplasmic inclusion bodies is a common cytopathological feature of neurodegenerative disease…”
Get full text

DcpS as a Therapeutic Target for Spinal Muscular Atrophy by Singh, Jasbir, Salcius, Michael, Liu, Shin-Wu, Staker, Bart L, Mishra, Rama, Thurmond, John, Michaud, Gregory, Mattoon, Dawn R, Printen, John, Christensen, Jeffery, Bjornsson, Jon Mar, Pollok, Brian A, Kiledjian, Megerditch, Stewart, Lance, Jarecki, Jill, Gurney, Mark E

“…Spinal muscular atrophy (SMA) is caused by deletion or mutation of both copies of the SMN1 gene, which produces an essential protein known as SMN. The severity…”
Get full text

Synthesis and Biological Evaluation of Novel 2,4-Diaminoquinazoline Derivatives as SMN2 Promoter Activators for the Potential Treatment of Spinal Muscular Atrophy by Thurmond, John, Butchbach, Matthew E. R, Palomo, Marty, Pease, Brian, Rao, Munagala, Bedell, Louis, Keyvan, Monica, Pai, Grace, Mishra, Rama, Haraldsson, Magnus, Andresson, Thorkell, Bragason, Gisli, Thosteinsdottir, Margret, Bjornsson, Jon Mar, Coovert, Daniel D, Burghes, Arthur H. M, Gurney, Mark E, Singh, Jasbir

“…Proximal spinal muscular atrophy (SMA) is an autosomal recessive disorder characterized by death of motor neurons in the spinal cord that is caused by deletion…”
Get full text

PDE4 subtypes in cancer by Hsien Lai, Samuel, Zervoudakis, Guston, Chou, Jesse, Gurney, Mark E., Quesnelle, Kelly M.

“…Cyclic nucleotide phosphodiesterases (PDE) break down cyclic nucleotides such as cAMP and cGMP, reducing the signaling of these important intracellular second…”
Get full text

Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial by Berry-Kravis, Elizabeth M., Harnett, Mark D., Reines, Scott A., Reese, Melody A., Ethridge, Lauren E., Outterson, Abigail H., Michalak, Claire, Furman, Jeremiah, Gurney, Mark E.

“…The goal of this study was to determine whether a phosphodiesterase-4D (PDE4D) allosteric inhibitor (BPN14770) would improve cognitive function and behavioral…”
Get full text

Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D) by Gurney, Mark E., Cogram, Patricia, Deacon, Robert M, Rex, Christopher, Tranfaglia, Michael

“…Fragile-X syndrome (FXS) patients display intellectual disability and autism spectrum disorder due to silencing of the X-linked, fragile-X mental retardation-1…”
Get full text

Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System by Zhang, Chong, Xu, Ying, Zhang, Han-Ting, Gurney, Mark E., O’Donnell, James M.

“…Inhibition of cyclic AMP (cAMP)-specific phosphodiesterase 4 (PDE4) has been proposed as a potential treatment for a series of neuropsychological conditions…”
Get full text

The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies by Gurney, Mark E

“…The discovery of mutations in the human SOD1 gene encoding Cu,Zn superoxide dismutase (Cu,Zn SOD) in patients with familial amyotrophic lateral sclerosis (ALS)…”
Get full text